Hepatitis Monthly

Published by: Kowsar

Efficacy and Safety of Reinforced Versus Standard Vaccine Schedule Towards Hepatitis B In Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Fabrizio Fabrizi 1 , * , Francesca Maria Donato 2 and Piergiorgio Messa 3
Authors Information
1 Division of Nephrology, Maggiore Hospital and IRCCS Foundation, Milano
2 Division of Gastroenterology, Maggiore Hospital and IRCCS Foundation, Milano
3 Division of Nephrology, Maggiore Hospital, University School of Medicine, Milano
Article information
  • Hepatitis Monthly: July 2017, 17 (7); e44179
  • Published Online: April 10, 2017
  • Article Type: Review Article
  • Received: November 21, 2016
  • Accepted: December 11, 2016
  • DOI: 10.5812/hepatmon.44179

To Cite: Fabrizi F, Maria Donato F, Messa P. Efficacy and Safety of Reinforced Versus Standard Vaccine Schedule Towards Hepatitis B In Chronic Kidney Disease: A Systematic Review and Meta-Analysis, Hepat Mon. 2017 ; 17(7):e44179. doi: 10.5812/hepatmon.44179.

Copyright © 2017, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Objective
3. Methods
4. Results
5. Discussion
  • 1. Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. Am J Nephrol. 2000; 20(1): 1-11[PubMed]
  • 2. Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003; 63(6): 2222-9[DOI][PubMed]
  • 3. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005; 18(1): 52-61[DOI][PubMed]
  • 4. Garcia Agudo R, Aoufi Rabih S, Barril Cuadrado G, Proy Vega B, Arias Arias A, Herruzo Gallego JA, et al. Spanish multicentre PIBHE study: Prevalence and immunization of chronic hepatitis B in haemodialysis patients in Spain. Nefrologia. 2016; 36(2): 126-32[DOI][PubMed]
  • 5. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant. 2009; 24(5): 1598-603[DOI][PubMed]
  • 6. Igaki N, Nakaji M, Moriguchi R, Akiyama H, Tamada F, Oimomi M, et al. An outbreak of fulminant hepatitis B in immunocompromised hemodialysis patients. J Gastroenterol. 2003; 38(10): 968-76[DOI][PubMed]
  • 7. Recommendations for Preventing Transmission of Infections Among Chronic Hemodialysis Patients. MMWR Morb Mortal Wkly Rep. 2001; 50: 1-43
  • 8. Donati D, Gastaldi L. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron. 1988; 50(2): 133-6[PubMed]
  • 9. Kapoor D, Aggarwal SR, Singh NP, Thakur V, Sarin SK. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat. 1999; 6(5): 405-9[PubMed]
  • 10. Marangi AL, Giordano R, Montanaro A, De Padova F, Schiavone MG, Dongiovanni G, et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis. 1994; 23(4): 537-42[PubMed]
  • 11. Fabrizi F, Di Filippo S, Marcelli D, Guarnori I, Raffaele L, Crepaldi M, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron. 1996; 72(4): 536-43[PubMed]
  • 12. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003; 42(6): 1184-92[PubMed]
  • 13. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10): 1006-12[DOI][PubMed]
  • 14. Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature. Controlled Clinical Trials. 1985; 6(4): 271-9[DOI]
  • 15. Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters M, et al. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. 2008; [PubMed]
  • 16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986; 7(3): 177-88[DOI]
  • 17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414): 557-60[DOI][PubMed]
  • 18. Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med. 2001; 20(23): 3625-33[PubMed]
  • 19. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988; 7(8): 889-94[PubMed]
  • 20. Klein S, Simes J, Blackburn GL. Total parenteral nutrition and cancer clinical trials. Cancer. 1986; 58(6): 1378-86[DOI]
  • 21. Benhamou E, Courouce AM, Jungers P, Laplanche A, Degos F, Brangier J, et al. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol. 1984; 21(3): 143-7[PubMed]
  • 22. Aronoff GR, Maxwell DR, Batteiger BE, Fineberg NS. Hepatitis B virus vaccine: a randomized trial of a reduced dose regimen in hemodialysis patients. Am J Kidney Dis. 1985; 6(3): 170-2[PubMed]
  • 23. Lelie PN, Reesink HW, de Jong-van Manen ST, Dees PJ, Reerink-Brongers EE. Immune response to a heat-inactivated hepatitis B vaccine in patients undergoing hemodialysis. Enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 micrograms. Arch Intern Med. 1985; 145(2): 305-9[PubMed]
  • 24. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis. 1988; 157(2): 332-7[PubMed]
  • 25. Bruguera M, Cremades M, Rodicio JL, Alcazar JM, Oliver A, Del Rio G, et al. Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am J Med. 1989; 87(3A): 30S-2S[PubMed]
  • 26. Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron. 1996; 73(3): 417-20[PubMed]
  • 27. Mauri JM, Valles M. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative Group of Girona. Nephrol Dial Transplant. 1997; 12(4): 729-32[PubMed]
  • 28. Deniz Ayli M, Ensari C, Ayli M, Mandiroglu F, Mut S. Effect of oral levamisole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients. Nephron. 2000; 84(3): 291-2[PubMed]
  • 29. McNulty CA, Bowen JK, Williams AJ. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules. Vaccine. 2005; 23(32): 4142-7[DOI][PubMed]
  • 30. Chow KM, Law MC, Leung CB, Szeto CC, Li PK. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract. 2006; 103(3)-93[DOI][PubMed]
  • 31. Chow KM, Lo SH, Szeto CC, Yuen SK, Wong KS, Kwan BC, et al. Extra-high-dose hepatitis B vaccination does not confer longer serological protection in peritoneal dialysis patients: a randomized controlled trial. Nephrol Dial Transplant. 2010; 25(7): 2303-9[DOI][PubMed]
  • 32. Jadoul M, Goubau P. Is anti-hepatitis B virus (HBV) immunization successful in elderly hemodialysis (HD) patients? Clin Nephrol. 2002; 58(4): 301-4[PubMed]
  • 33. Khedmat H, Aghaei A, Ghamar-Chehreh ME, Agah S. Sex bias in response to hepatitis B vaccination in end-stage renal disease patients: Meta-analysis. World J Nephrol. 2016; 5(1): 115-24[DOI][PubMed]
  • 34. Fernandez E, Betriu MA, Gomez R, Montoliu J. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant. 1996; 11(8): 1559-63[PubMed]
  • 35. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol. 1996; 16(2): 95-7[PubMed]
  • 36. Ahuja TS, Kumar S, Mansoury H, Rodriguez H, Kuo YF. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int. 2005; 67(3): 1136-41[DOI][PubMed]
  • 37. Alavian SM, Tabatabaei SV. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature. Vaccine. 2010; 28(22): 3773-7[DOI][PubMed]
  • 38. Sennesael JJ, Van der Niepen P, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int. 1991; 40(1): 121-8[PubMed]
  • 39. Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol. 1990; 11(3): 385-7[PubMed]
  • 40. Jibani MM, Heptonstall J, Walker AM, Bloodworth LO, Howard AJ. Hepatitis B immunization in UK renal units: failure to put policy into practice. Nephrol Dial Transplant. 1994; 9(12): 1765-8[PubMed]
  • 41. Mulley WR, Le ST, Ives KE. Primary seroresponses to double-dose compared with standard-dose hepatitis B vaccination in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2016; [DOI][PubMed]
  • 42. Chen YC, Su YC, Li CY, Wu CP, Lee MS. A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. Kidney Int. 2015; 87(5): 1030-8[DOI][PubMed]
  • 43. Wu T, Li Y, Bian Z, Liu G, Moher D. Randomized trials published in some Chinese journals: how many are randomized? Trials. 2009; 10: 46[DOI][PubMed]
  • 44. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998; 352(9128): 609-13[DOI][PubMed]
  • 45. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999; 33(2): 356-60[PubMed]
  • 46. Surquin M, Tielemans CL, Kulcsar I, Ryba M, Voros P, Mat O, et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine. Kidney Int. 2010; 77(3): 247-55[DOI][PubMed]
  • 47. Fabrizi F, Tarantino A, Castelnovo C, Martin P, Messa P. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study. Kidney Blood Press Res. 2015; 40(6): 584-92[DOI][PubMed]
  • 48. Weinstein T, Chagnac A, Boaz M, Ori Y, Herman M, Zevin D, et al. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract. 2004; 97(2)-72[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments